Thyroid status and nitric oxide in rat arterial vessels

R M McAllister, I Albarracin, E M Price¹, T K Smith, J R Turk¹
and K D Wyatt

Departments of Anatomy and Physiology and Kinesiology, Kansas State University, Manhattan, Kansas 66506, USA

¹Department of Veterinary Biomedical Sciences, University of Missouri, Columbia, Missouri 65211, USA

(Requests for offprints should be addressed to R M McAllister, Department of Anatomy and Physiology, Kansas State University, 228 Coles Hall, Manhattan, Kansas 66506, USA; Email: mcallist@vet.ksu.edu)

Abstract

Thyroid disease has profound effects on cardiovascular function. Hypo- and hyperthyroidism, for example, are associated with reduced and increased maximal endothelium-dependent vasodilation respectively. We therefore hypothesized that the capacity for vascular nitric oxide (NO) formation is decreased in hypothyroidism and increased in hyperthyroidism. To test this hypothesis, rats were made hypothyroid (HYPO) with propylthiouracil or hyperthyroid (HYPER) with triiodothyronine over 3–4 months. Compared with euthyroid control rats (EUT), HYPO exhibited blunted growth and lower citrate synthase activity in the soleus muscle; HYPER exhibited left ventricular hypertrophy and higher citrate synthase activity in the soleus muscle ($P < 0.05$ for all effects). The capacity for NO formation was determined in aortic extracts by formation of [³H]L-citrulline from [³H]L-

arginine, i.e. NO synthase (NOS) activity. Thyroid status modulated NOS activity (EUT, 36.8 ± 5.5 fmol/h per mg protein; HYPO, 26.0 ± 7.9 ; HYPER, 64.6 ± 12.7 ; $P < 0.05$, HYPER vs HYPO). Expression of endothelial and neural isoforms of NOS was modulated by thyroid status in a parallel fashion. Capacity for responding to NO was also determined via measuring cGMP concentration in aortae incubated with sodium nitroprusside. Stimulated cGMP formation was also modulated by thyroid status (EUT, 73.0 ± 20.2 pmol/mg protein; HYPO, 152.4 ± 48.7 ; HYPER, 10.4 ± 2.6 ; $P < 0.05$, HYPER vs HYPO). These data indicate that thyroid status alters capacities for both formation of and responding to NO. The former finding may contribute to previous findings concerning vascular function in thyroid disease states.

Journal of Endocrinology (2005) **185**, 111–119

Introduction

Thyroid disease is estimated to affect 10% of the population (Tunbridge & Caldwell 1991, Canaris *et al.* 2000). A hallmark of two common forms of thyroid disease, hypo- and hyperthyroidism, is exercise intolerance. Several studies have examined various mechanisms potentially responsible for exercise intolerance in these disease states. In hypothyroidism, it appears that cardiovascular dysfunction is largely responsible for poor exercise tolerance; in hyperthyroidism, other factors such as hyperthermia and altered patterns of substrate utilization are implicated (cf. McAllister *et al.* 1995a).

Cardiovascular dysfunction during exercise in hypothyroidism is profound. We have previously reported that skeletal muscle blood flow during treadmill running is reduced ~50% in hypothyroid rats compared with their euthyroid counterparts (McAllister *et al.* 1995b). Lower blood flow would impair delivery of O₂ and substrates to exercising muscle. When vasomotor responses were determined for euthyroid and hypothyroid rats, endothelium-dependent dilation was also found to be

blunted in isolated aortae (Delp *et al.* 1995, McAllister *et al.* 2000) and isolated perfused kidneys (Vargas *et al.* 1995) in the hypothyroid state. Paradoxically, given that exercise tolerance is reduced, hyperthyroidism is associated with enhanced muscle blood flow during exercise (Frey 1967, McAllister *et al.* 1995c) and augmented endothelium-dependent vasodilation (Scivoletto *et al.* 1986, Vargas *et al.* 1995, McAllister *et al.* 1998, 2000, Honda *et al.* 2000). Thus, in both thyroid disease states, alterations in endothelium-dependent vasodilation are consistent with patterns of blood flow to exercising skeletal muscle.

Endothelium-independent vasodilation has generally been reported to be normal in both the hypothyroid (Delp *et al.* 1995, McAllister *et al.* 2000) and hyperthyroid states (McAllister *et al.* 1998, 2000), although exceptions have been reported (Vargas *et al.* 1995, Honda *et al.* 2000). Collectively, these findings suggest that thyroid status primarily affects the vascular endothelium. Endothelium-dependent dilation of the rat aorta is primarily mediated by nitric oxide (NO) (Delp *et al.* 1993). We therefore hypothesized that altered endothelium-dependent vasodilation with changes in thyroid status is due to changes

in the capacity for NO formation, as reflected by NO synthase (NOS) activity. We also hypothesized that the response to NO, as reflected by the capacity of vascular smooth muscle to generate cGMP, is not altered by thyroid status.

Materials and Methods

Animal treatments

Two series of male Sprague–Dawley rats (Charles River, Wilmington, MA, USA), initially weighing 150–175 g, were housed three per cage in a room with controlled temperature (20–21 °C) and light (12 h light:12 h darkness). In each series, rats were randomly assigned to one of three groups: euthyroid control (EUT), hypothyroid (HYPO) and hyperthyroid (HYPER). HYPO rats were made hypothyroid over a 3–4 month period with propylthiouracil in their drinking water (0.04 g/100 ml), as done previously (Delp *et al.* 1995, McAllister *et al.* 1995b, 2000). HYPER rats were made hyperthyroid over 3–4 months with i.p. injections of triiodothyronine (300 µg/kg in 0.50 mM NaOH) on alternate days, as done previously (McAllister *et al.* 1995c, 1998, 2000). All rats were allowed free access to food and water except for EUT, which were slightly food-restricted (~90% of normal food intake) over the final month of the treatment period to match body weights with those of HYPO and HYPER. This mild degree of food restriction would not affect thyroid status in EUT, since only either starvation or severe food restriction has been reported to reduce thyroid hormone levels (cf. Danforth & Burger 1989). All treatments were approved by the Institutional Animal Care and Use Committee of Kansas State University, and were in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Treatment efficacy

Efficacy of propylthiouracil and triiodothyronine treatments was assessed by determination of citrate synthase activity in the soleus muscle, gain in body weight during the treatment period and left ventricular weight/body weight ratio. Activity of citrate synthase, a marker enzyme for oxidative capacity, was determined spectrophotometrically (Shimadzu UV-1201, Shimadzu, Kyoto, Japan) according to the method of Srere (1969), as done previously to document hypo- and hyperthyroidism (Delp *et al.* 1995, McAllister *et al.* 1995b,c, 1998, 2000).

NOS activity

With the first series of rats (NOS Series), capacity for vascular NO formation was assessed by determining NOS activity in aortic extracts of EUT, HYPO and HYPER. Extracts of aortae were prepared in the following manner:

the entire aorta was excised, quickly cleaned of fat and connective tissue under a dissecting microscope (Nikon, Melville, NY, USA), and cut into rings ~1 mm in axial length. Vascular rings were transferred to microcentrifuge tubes containing 250 µl of a buffer solution containing (in mM unless otherwise indicated): 50 Tris–HCl, 0.10 EDTA, 0.10 EGTA, 0.10 ml/100 ml β-mercaptoethanol, 20 CHAPS, 1.0 phenylmethylsulfonyl fluoride, 0.002 leupeptin and 0.001 pepstatin A, pH 7.8. Vascular rings were sonicated (Fisher Sonic Dismembrator 60, Fisher, Pittsburgh, PA, USA) in this buffer solution (5 s, three times), and then centrifuged at 250 000 g (Beckman TL-100 ultracentrifuge, Beckman, Palo Alto, CA, USA) for 30 min at 4 °C. Aliquots of the resultant supernatant were assayed for NOS activity.

NOS activity was determined according to the method of Pollock *et al.* (1991), in which the conversion of [³H]L-arginine to [³H]L-citrulline is measured. Aortic extracts were incubated for 1 h at 27 °C in a buffer solution with (final concentration, in mM unless otherwise indicated): 50 Tris–HCl, 54 L-valine, 1.2 MgCl₂, 1.0 NADPH, 0.01 tetrahydrobiopterin, 0.005 L-arginine, 50 U/ml calmodulin and 0.002 FAD, pH 7.8. [³H]L-arginine (0.010 mCi; New England Nuclear, Boston, MA, USA) was also included. Aliquots of extracts were incubated in this buffer solution that contained CaCl₂ (1.78 mM) and in buffer solution that did not contain CaCl₂ to determine Ca²⁺-dependent NOS activity. Appropriate backgrounds (i.e. aliquots of buffer solution rather than aortic extract) were incubated in parallel. At the end of the incubation period, the NOS reaction was arrested with addition of a buffer solution containing 20 mM HEPES and 8.0 mM EDTA, pH 5.5. Reaction mixtures were loaded onto cation exchange columns (Dowex AG 50WX-8, Na⁺ form; Bio-Rad), and [³H]L-citrulline was eluted from columns with 0.50 ml (×2) ddH₂O. Scintillation fluid was added to eluent, and samples were counted in a liquid scintillation counter (Packard, Meriden, CT, USA).

NOS expression

Western blotting was used to determine expression of the endothelial and neural isoforms of NOS (eNOS and nNOS respectively), as well as that of guanylate cyclase (GC), in aortae from EUT, HYPO and HYPER. Aortic extracts prepared for determination of NOS activity (see above) were subsequently used in Western blotting experiments. For each sample (eNOS, nNOS), a volume of extract containing 5.0 µg total protein was used. For GC, 2.5 µg total protein were used. Samples were loaded onto a 4–12% Bis-Tris gel, and electrophoresed at 200 V for 50 min. Transfer to polyvinylidene difluoride membrane was done at 200 mA for 2 h. Blocking was done for 60 min in Tris-buffered saline with 0.10 ml/100 ml Tween 20 and 5.0 g/100 ml non-fat milk (TBST-milk). Following blocking, overnight incubation with a primary antibody

(in TBST-milk) against eNOS (1:1250; BD Transduction Laboratories), nNOS (1:1000; BD Transduction Laboratories), GC (1:5000; Cayman Chemical, Ann Arbor, MI, USA), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:2000; Chemicon, Temecula, CA, USA) was done. Separate membranes were generated and probed for eNOS, nNOS and GC; all membranes were subsequently re-probed for GAPDH. After washing, blots were incubated for 60 min with a secondary antibody (horseradish peroxidase-conjugated anti-mouse; 1:2500, in TBST-milk; Sigma-Aldrich), washed, and then visualized on film using enhanced chemiluminescence (Amersham Pharmacia Biotech). Densitometry software (NIH) was used to quantify protein expression, with eNOS, nNOS and GC expression being normalized to GAPDH expression.

Immunohistochemistry

As described in detail previously (Henderson *et al.* 2004), 5 µm sections of fixed (10 ml/100 ml formalin), paraffin-embedded aortic rings were cut with an automated microtome (Microm, Walldorf, Germany), floated onto positively-charged slides, and de-paraffinized. Sections were incubated with avidin-biotin two-step blocking solution (Vector SP-2001, Vector, Burlingame, CA, USA) to inhibit background staining and with hydrogen peroxide (3 ml/100 ml) to inhibit endogenous peroxidase. Non-serum protein block (Dako X909, Dako, Carpinteria, CA, USA) was used to inhibit non-specific binding. Tissue sections were incubated overnight with primary antibodies against eNOS (mouse monoclonal, 1:800; BD Transduction Laboratories, San Diego, CA, USA) and nNOS (rabbit polyclonal, 1:100; Zymed, San Francisco, CA, USA) at 4 °C. After washing, sections were incubated with biotinylated anti-mouse or rabbit secondary antibodies in PBS containing 15 mM sodium azide and peroxidase-labeled streptavidin (Dako LSAB+ kit, peroxidase; K0690). For negative controls, histological sections were prepared as described above, but incubation with primary antibody was excluded from the protocol. Sections were examined and photographed using an Olympus BX40 photomicroscope (Olympus, St. Louis, MO, USA).

cGMP formation

With the second series of rats (cGMP Series), the concentration of cGMP under basal conditions and upon stimulation with an NO donor was determined in aortae from EUT, HYPO and HYPER. To prepare aortae for cGMP determination, vessels previously excised, cleaned and frozen at -80 °C (entire aorta for basal levels, abdominal aorta for stimulated levels) were opened longitudinally, pinned to the bottom of a dissecting dish filled with ice-cold DMEM-HEPES modification buffer solution, pH 7.4, and gently denuded of their endothelium with

a cotton-tipped applicator. Vessels were then placed in DMEM-HEPES modification buffer solution with 1.0 mM isobutylmethylxanthine, pH 7.4 (basal) or the same buffer solution with 10⁻⁴ M sodium nitroprusside, an NO donor, also included (stimulated). After a 30 min incubation period, the GC reaction was arrested with 70% trichloroacetic acid and then neutralized with 10.0 M KOH. Vessels were homogenized (IKA Labortechnik T25 homogenizer, Labortechnik, Staufen, Germany) using 10 s bursts until complete homogenization was achieved. Homogenates were centrifuged (Damon PR-J centrifuge) at 1500 g for 10 min. The resultant supernatant was assayed for cGMP concentration; the pellet was used for determination of protein concentration (see below). Concentrations of cGMP in supernatants was determined using an RIA kit (Amersham Pharmacia Biotech).

In addition to determining aortic cGMP concentration, experiments were conducted to determine release of cGMP from aortae. Stimulation of cGMP formation in whole aortae (sectioned into 1 mm axial length rings) using an NO donor was done as described above. After centrifugation (1500 g for 10 min) to pellet aortic rings, cGMP concentration in supernatants was determined with an enzyme immunoassay kit (Assay Designs, Ann Arbor, MI, USA).

Protein concentration

Protein concentration was determined on aortic extracts to normalize NOS activities, and on pellets of homogenized vessels to normalize cGMP concentrations. Protein concentration was determined with a kit utilizing the Bradford procedure (Bio-Rad).

Statistical analysis

All data are presented as means ± S.E. Data for EUT, HYPO and HYPER were analyzed using one-way ANOVA (Steel & Torrie 1980). When ANOVA indicated a difference among groups, the Tukey test was used as a post-hoc test to discern differences between pairs of groups (Steel & Torrie 1980). *P* < 0.05 was considered significant for all analyses.

Results

Treatment efficacy

Treatment of rats with propylthiouracil successfully induced the hypothyroid state. Citrate synthase activity was lower in HYPO than EUT in the soleus muscle for both series of rats (Fig. 1). In addition, HYPO failed to increase body weight at a normal rate, reflected by lower final body weights than those of EUT and HYPER, in both series (Table 1). Similarly, two lines of evidence indicated that treatment of rats with triiodothyronine induced the

Figure 1 Citrate synthase activity in soleus muscles of rats of the NOS Series and cGMP Series. Values are means $\pm$ S.E.; $n=7$, 7 and 8 for Euthyroid (open bars), Hypothyroid (hatched bars) and Hyperthyroid (stippled bars) respectively in the NOS Series; $n=12$, 11 and 10 for Euthyroid, Hypothyroid and Hyperthyroid respectively in the cGMP Series. *Different from Euthyroid, $P<0.05$; †different from Hypothyroid, $P<0.05$.

Table 1 Indicators of treatment efficacy. Values are means $\pm$ S.E. For NOS Series $n=7$, 7 and 8 for Euthyroid, Hypothyroid and Hyperthyroid respectively; for cGMP Series $n=12$, 10 and 10 for Euthyroid, Hypothyroid and Hyperthyroid respectively

	NOS Series	cGMP Series
LV weight/body weight ratio (mg/g)		
Euthyroid	2.03 $\pm$ 0.08	1.93 $\pm$ 0.03
Hypothyroid	1.86 $\pm$ 0.05	2.10 $\pm$ 0.06
Hyperthyroid	2.50 $\pm$ 0.10*†	2.45 $\pm$ 0.07*†
Final body weight (g)		
Euthyroid	497 $\pm$ 15	516 $\pm$ 15
Hypothyroid	284 $\pm$ 6*	253 $\pm$ 6*
Hyperthyroid	478 $\pm$ 15†	493 $\pm$ 15†

LV, left ventricle. *Different from Euthyroid in same series, $P<0.05$; †different from Hypothyroid in same series, $P<0.05$.

hyperthyroid state. First, citrate synthase activity was increased in HYPER (vs EUT) soleus muscles in both series of rats (Fig. 1). Secondly, left ventricular weight/body weight ratio was increased in HYPER compared with EUT (Table 1), reflecting left ventricular hypertrophy.

NOS activity and expression

Figure 2 illustrates Ca^{2+} -dependent NOS activity for EUT, HYPO and HYPER aortic extracts. Thyroid status significantly modulated NOS activity, with values for HYPER being more than twice those for HYPO ($P<0.05$). Neither HYPO nor HYPER, however, differed significantly from EUT in NOS activity. In two control experiments, aortae from normal rats demonstrated a mean reduction of 81% in Ca^{2+} -dependent NOS activity when treated with the competitive NOS inhibitor N^G -monomethyl-L-arginine (4.29 mM) (Pollock *et al.*

Figure 2 Ca^{2+} -dependent NOS activity in aortic extracts. Values are means $\pm$ S.E.; $n=7$, 7 and 8 for Euthyroid (open bar), Hypothyroid (hatched bar) and Hyperthyroid (stippled bar) respectively. †Different from Hypothyroid, $P<0.05$.

1991). eNOS and nNOS protein expression differed significantly between HYPER and HYPO in a parallel fashion, as illustrated in Fig. 3. Immunohistochemistry for eNOS (Fig. 4) and nNOS (Fig. 5) demonstrated markedly greater nNOS expression in vascular smooth muscle of HYPER (Fig. 5). Expression of eNOS was confined to endothelium in all groups and did not differ visibly among groups (Fig. 4).

cGMP concentration

Basal levels of cGMP were not different among groups, being 0.214 ± 0.055 , 0.181 ± 0.051 and 0.101 ± 0.027 pmol/mg protein for EUT ($n=4$), HYPO ($n=3$) and HYPER ($n=4$) respectively. Figure 6A illustrates data for stimulated levels of cGMP. Stimulation of GC with sodium nitroprusside increased cGMP concentration substantially over basal levels for EUT, HYPO and HYPER. Stimulated cGMP concentration attained was, similar to NOS activity, significantly modulated by thyroid status. Values for HYPO were significantly greater than those for HYPER ($P<0.05$); however, neither HYPO nor HYPER were significantly different from EUT. GC protein expression did not differ significantly among EUT, HYPO and HYPER (Fig. 6B).

Thyroid status can affect tissue protein concentration; thus, data for cGMP levels were also expressed and analyzed on a per tissue weight basis. Thyroid status did not affect basal cGMP concentration (EUT, 7.2 ± 1.0 pmol/g; HYPO, 12.7 ± 3.2 ; HYPER, 6.2 ± 1.5 ; ns). Stimulated cGMP concentration was, however, modulated by thyroid state (EUT, 463.8 ± 110.1 pmol/g; HYPO, 334.5 ± 65.6 ; HYPER, 82.2 ± 8.8 ; $P<0.05$, HYPER vs EUT, HYPO).

Figure 3 Expression of eNOS (A) and nNOS (B). Values are means $\pm$ s.e.; $n=7$, 6 and 8 for Euthyroid (open bars), Hypothyroid (hatched bars) and Hyperthyroid (stippled bars) respectively for eNOS; $n=6$, 6 and 8 for Euthyroid, Hypothyroid and Hyperthyroid respectively for nNOS. DU, densitometry units, normalized to GAPDH. †Different from Hypothyroid, $P<0.05$. Insets are representative Western blots for eNOS and nNOS. EU, Euthyroid; HO, Hypothyroid; HY, Hyperthyroid; HU, human umbilical vein endothelial cell extract.

When release of cGMP from vascular smooth muscle was determined, cGMP concentration in the incubation medium was also elevated in HYPO (EUT, 0.057 ± 0.11 pmol/ml per mg wet weight, $n=7$; HYPO, 0.110 ± 0.017 , $n=9$; HYPER, 0.072 ± 0.010 , $n=8$; $P<0.05$, HYPO vs EUT).

Discussion

The key findings of this study are that capacities for both formation of and responding to NO in a rat arterial vessel are modulated by thyroid status. The hyperthyroid state was associated with increased capacity for NO formation,

but reduced capacity for responding to NO, compared with the hypothyroid state. Capacity for NO formation, assessed by NOS activity, is primarily a property of the vascular endothelium. Capacity for responding to NO, estimated by NO donor-stimulated concentration of cGMP, resides in vascular smooth muscle. These data indicate that thyroid status affects more than the endothelial layer of the vascular wall, contrary to what a majority of previous studies had suggested.

Rat models of hypo- and hyperthyroidism

Treatment of rats with propylthiouracil was successful in inducing the hypothyroid state. Citrate synthase activity,

Figure 4 Immunohistochemical analysis of Euthyroid, Hypothyroid and Hyperthyroid aortae for eNOS. Vascular lumen located at the top of each panel; non-immune panel represents section not incubated with antibody to eNOS. Note positive staining for eNOS in endothelium of vascular wall.

an index of oxidative capacity, was reduced in the soleus muscle of HYPO. This effect of hypothyroidism on mitochondrial protein content of skeletal muscle has been repeatedly reported for rodent muscle by us (Delp *et al.* 1995, McAllister *et al.* 1995b, 2000) and others (e.g. Ianuzzo *et al.* 1977). Conversely, treatment with triiodothyronine was associated with increased citrate synthase activity, as reported previously by us (McAllister *et al.* 1995c, 1998, 2000) and others (e.g. Ianuzzo *et al.* 1977). HYPO also exhibited blunted growth; in addition, HYPER demonstrated left ventricular hypertrophy. These findings, all hallmarks of hypo- and hyperthyroidism, indicate that our rat models of thyroid disease are valid.

Capacity for NO formation

Although neither hypo- nor hyperthyroid status significantly altered NOS activity relative to the euthyroid state, the capacity for NO formation was clearly greater in aortae

from HYPER than in those from HYPO. Our findings for aortic NOS activity in different thyroid states resemble those reported by Quesada *et al.* (2002). Further, these findings are consistent with earlier findings concerning vascular function. We (Delp *et al.* 1995, McAllister *et al.* 2000) and others (Vargas *et al.* 1995) have found endothelium-dependent dilation of rat vasculature to be blunted in hypothyroidism; conversely, we (McAllister *et al.* 1998, 2000) and others (Scivoletto *et al.* 1986, Vargas *et al.* 1995, Honda *et al.* 2000) have observed augmented endothelium-dependent vasodilation in the hyperthyroid state. Since a primary mediator of endothelium-dependent dilation in vasculature of the rat is NO (Delp *et al.* 1993), our findings collectively suggest that alterations in endothelium-dependent vasodilation with changes in thyroid status are, in part, accounted for by an altered capacity for NO formation. It is clear, however, that changes in NO formation do not solely account for altered endothelium-dependent vasodilation. Vascular function

Figure 5 Immunohistochemical analysis of Euthyroid, Hypothyroid and Hyperthyroid aortae for nNOS. Vascular lumen located at top of each panel; non-immune panel represents a section not incubated with antibody to nNOS. Note positive staining for nNOS in smooth muscle of vascular wall, and greater staining for nNOS in the Hyperthyroid panel.

studies have demonstrated differences in endothelium-dependent dilation among EUT, HYPO and HYPER, whereas NOS activity in the present study only differed significantly between HYPO and HYPER. Changes in formation of vasodilatory prostaglandins and/or endothelium-derived hyperpolarizing factors may also contribute to alterations in endothelium-dependent vasodilation with altered thyroid status.

Interestingly, both eNOS and nNOS protein expression were modulated in HYPO and HYPER in a manner consistent with NOS activity. Our data for NOS activity represent capacity for Ca^{2+} -dependent NO formation; eNOS and nNOS are Ca^{2+} -dependent isoforms of this enzyme (cf. Pollock *et al.* 1991). While the significance of modulation of eNOS expression for endothelium-dependent vasodilation is clear, that of alterations in nNOS expression with changes in thyroid status is less clear. It has been postulated that nNOS, which appears to be expressed only in vascular smooth muscle, may modulate

contractile mechanisms (Brophy *et al.* 2000). Our immunohistochemical findings are in agreement with this earlier study; indeed, there was a marked increase in nNOS expression in vascular smooth muscle of HYPER aorta (Fig. 5). While the functional significance of this finding is uncertain, increased nNOS expression likely contributed to greater Ca^{2+} -dependent NOS activity in HYPER.

Modulation of eNOS and nNOS expression by thyroid status may involve several stimuli, two of which are thyroid hormone concentration and chronic level of blood flow/shear stress. Hypo- and hyperthyroidism have effects on protein expression in most tissues (Yen 2001); their effects on skeletal muscle metabolic and contractile protein expression are particularly well established (Ianuzzo *et al.* 1977, Caiozzo & Haddad 1996). It is unknown whether thyroid hormone affects protein expression in the vascular wall. Effects of chronically increased blood flow/shear stress on the vascular endothelium are better understood.

Figure 6 (A) Concentration of cGMP in aortae stimulated with sodium nitroprusside. Values are means $\pm$ S.E.; $n=8$, 8 and 8 for Euthyroid (open bar), Hypothyroid (hatched bar) and Hyperthyroid (stippled bar) respectively. †Different from Hypothyroid, $P<0.05$. (B) Expression of GC protein. Values are mean $\pm$ S.E.; $n=6$, 5 and 8 for Euthyroid (open bar), Hypothyroid (hatched bar) and Hyperthyroid (stippled bar) respectively. DU, densitometry units, normalized to GAPDH. There are no differences in GC expression among groups. Inset is a representative Western blot for GC. EU, Euthyroid; HO, Hypothyroid; HY, Hyperthyroid.

Studies using cultured endothelial cells exposed to increased shear stress (Nishida *et al.* 1992, Noris *et al.* 1995, Ranjan *et al.* 1995, Uematsu *et al.* 1995), and whole blood vessels studied *in vitro* after a period of chronically increased blood flow (Miller *et al.* 1986, Miller & Vanhoutte 1988, Miller & Burnett 1992, Nadaud *et al.* 1996), have reported increased endothelium-dependent vasodilation, increased NOS activity, and/or increased eNOS expression. It is therefore possible that increased cardiac output, a feature of human hyperthyroidism (Martin *et al.* 1991) and animal models of the disease (cf. Morkin *et al.* 1983), led to increased eNOS expression in HYPER via a chronic increase in shear stress on the aortic endothelium.

Response to NO

An unexpected finding in this study was that thyroid status also modulated the response of vascular smooth muscle to NO. While aortae from EUT, HYPO and HYPER all demonstrated large increases in cGMP concentration upon stimulation with an NO donor (i.e. stimulated vs basal cGMP concentrations), the increase in HYPO was markedly greater than that in HYPER (Fig. 6A). Normalizing cGMP concentration to tissue weight, rather than tissue protein concentration, did not change this finding. We were, however, unable to confirm depressed capacity for cGMP formation in HYPER when we determined cGMP release from vascular smooth muscle. Nonetheless, our

data uniformly indicate that capacity for cGMP formation is increased in HYPO. This finding was unexpected, since we have previously found that aortae from hypothyroid rats (Delp *et al.* 1995, McAllister *et al.* 2000) exhibit normal relaxation responses to sodium nitroprusside at the same concentration used in the present study to stimulate GC. Further, we found that GC protein expression was similar among EUT, HYPO and HYPER, a finding inconsistent with alterations in the capacity for stimulated cGMP formation. Differences in breakdown of cGMP do not underlie our findings, since we included isobutylmethylxanthine, a phosphodiesterase inhibitor, in our assay system to eliminate cGMP breakdown as a confounding variable. These findings emphasize the complexity of vascular cGMP formation and may indicate that acute regulation of GC (e.g. phosphorylation of GC, cytosolic Ca^{2+} concentration; cf. Friebe & Koesling 2003), rather than simple modulation of GC protein amount, is most important in determining cGMP formation in different thyroid states.

Perspectives

Exercise intolerance in hypothyroidism appears to be largely accounted for by cardiovascular dysfunction. Skeletal muscle blood flow during exercise is blunted (McAllister *et al.* 1995b), as is endothelium-dependent vasodilation (Delp *et al.* 1995, Vargas *et al.* 1995, McAllister *et al.* 2000). Conversely, hyperthyroidism is associated with augmented muscle blood flow during exercise (Frey 1967, McAllister *et al.* 1995c) and with enhanced endothelium-dependent vasodilation (Scivoletto *et al.* 1986, Vargas *et al.* 1995, McAllister *et al.* 1998, 2000, Honda *et al.* 2000). Our findings for NOS activity, as well as for eNOS and nNOS protein expression, suggest that changes in capacity for NO formation contribute to alterations in endothelium-dependent vasodilation in hypo- and hyperthyroidism. They may, therefore, contribute to the mechanistic basis for altered skeletal muscle blood flow during exercise in thyroid disease states.

Acknowledgements

The technical assistance of Amy Barker, Emily Buhr, Stephanie Coovert and Kasee Hildenbrand is gratefully acknowledged. Also acknowledged is provision of equipment essential to the conduct of this research by Drs Lisa Freeman and George Stewart.

Funding

This research was supported by NIH HL 57226 and AHA-KS-98-GB-25, as well as by a Research Career Enhancement Award from the American Physiological

Society. T K S was a Howard Hughes Medical Institute (HHMI) Research Scholar, supported by a HHMI Undergraduate Biology Education Program grant to Kansas State University. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References

- Brophy CM, Knoepf L, Xin J & Pollock JS 2000 Functional expression of NOS 1 in vascular smooth muscle. *American Journal of Physiology – Heart and Circulatory Physiology* **278** H991–H997.
- Caiozzo VJ & Haddad F 1996 Thyroid hormone: modulation of muscle structure, function, and adaptive responses to mechanical loading. *Exercise and Sport Sciences Reviews* **24** 321–361.
- Canaris GJ, Manowitz NR, Mayor G & Ridgway EC 2000 The Colorado thyroid disease prevalence study. *Archives of Internal Medicine* **160** 526–534.
- Danforth E & Burger AG 1989 The impact of nutrition on thyroid hormone physiology and action. *Annual Reviews of Nutrition* **9** 201–227.
- Delp MD, McAllister RM & Laughlin MH 1993 Exercise training alters endothelium-dependent vasoreactivity of rat abdominal aorta. *Journal of Applied Physiology* **75** 1354–1363.
- Delp MD, McAllister RM & Laughlin MH 1995 Exercise training alters aortic vascular reactivity in hypothyroid rats. *American Journal of Physiology – Heart and Circulatory Physiology* **268** H1428–H1435.
- Frey HMM 1967 Peripheral circulatory and metabolic consequences of thyrotoxicosis. IV. Blood flow in resting and working calf muscle in patients with thyrotoxicosis before and after treatment. *Scandinavian Journal of Clinical and Laboratory Investigation* **19** 143–148.
- Friebe A & Koesling D 2003 Regulation of nitric oxide-sensitive guanylyl cyclase. *Circulation Research* **93** 96–105.
- Henderson KK, Turk JR, Rush JWE & Laughlin MH 2004 Endothelial function in coronary arterioles from pigs with early-stage coronary disease induced by high-fat, high-cholesterol diet: effect of exercise. *Journal of Applied Physiology* **97** 1159–1168.
- Honda H, Iwata T, Mochizuki T & Kogo H 2000 Changes in vascular reactivity induced by acute hyperthyroidism in isolated aortae. *General Pharmacology* **34** 429–434.
- Ianuzzo D, Patel P, Chen V, O'Brien P & Williams C 1977 Thyroidal trophic influence on skeletal muscle myosin. *Nature* **270** 74–76.
- Martin WH, Spina RJ, Korte E, Yarasheski KE, Angelopoulos TJ, Nemeth PM & Saffitz JE 1991 Mechanisms of impaired exercise capacity in short duration experimental hyperthyroidism. *Journal of Clinical Investigation* **88** 2047–2053.
- McAllister RM, Delp MD & Laughlin MH 1995a Thyroid status and exercise tolerance: cardiovascular and metabolic considerations. *Sports Medicine* **20** 189–198.
- McAllister RM, Delp MD, Thayer KA & Laughlin MH 1995b Muscle blood flow during exercise in sedentary and trained hypothyroid rats. *American Journal of Physiology – Heart and Circulatory Physiology* **268** H1949–H1954.
- McAllister RM, Sansone JC & Laughlin MH 1995c Effects of hyperthyroidism on muscle blood flow during exercise in rats. *American Journal of Physiology – Heart and Circulatory Physiology* **268** H330–H335.
- McAllister RM, Grossenburg VD, Delp MD & Laughlin MH 1998 Effects of hyperthyroidism on vascular contractile and relaxation responses. *American Journal of Physiology – Endocrinology and Metabolism* **274** E946–E953.
- McAllister RM, Luther KL & Pfeifer PC 2000 Thyroid status and response to endothelin-1 in rat arterial vessels. *American Journal of Physiology – Endocrinology and Metabolism* **279** E252–E259.
- Miller VM & Burnett JC 1992 Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries. *American Journal of Physiology – Heart and Circulatory Physiology* **263** H103–H108.
- Miller VM & Vanhoutte PM 1988 Enhanced release of endothelium-derived factor(s) by chronic increases in blood flow. *American Journal of Physiology – Heart and Circulatory Physiology* **255** H446–H451.
- Miller VM, Aarhus LL & Vanhoutte PM 1986 Modulation of endothelium-dependent responses by chronic alterations of blood flow. *American Journal of Physiology – Heart and Circulatory Physiology* **251** H520–H527.
- Morkin E, Flink IL & Goldman S 1983 Biochemical and physiologic effects of thyroid hormone on cardiac performance. *Progress in Cardiovascular Disease* **25** 435–464.
- Nadaud S, Philippe M, Arnal J-F, Michel J-B & Soubrier F 1996 Sustained increase in aortic endothelial nitric oxide synthase expression *in vivo* in a model of chronic high blood flow. *Circulation Research* **79** 857–863.
- Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, Nerem RM, Alexander RW & Murphy TJ 1992 Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. *Journal of Clinical Investigation* **90** 2092–2096.
- Noris M, Morigi M, Donadelli R, Aiello S, Foppolo M, Todeschini M, Orsio S, Remuzzi G & Remuzzi A 1995 Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. *Circulation Research* **76** 536–543.
- Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HHHW, Nakane M & Murad F 1991 Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. *PNAS* **88** 10480–10484.
- Quesada A, Sainz J, Wangenstein R, Rodriguez-Gomez I, Vargas F & Osuna A 2002 Nitric oxide synthase activity in hyperthyroid and hypothyroid rats. *European Journal of Endocrinology* **147** 117–122.
- Ranjan V, Xiao Z & Diamond SL 1995 Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress. *American Journal of Physiology – Heart and Circulatory Physiology* **269** H550–H555.
- Scivoletto R, Fortes ZB & Garcia-Leme J 1986 Thyroid hormones and vascular reactivity: role of the endothelial cell. *European Journal of Pharmacology* **129** 271–278.
- Srere PA 1969 Citrate synthase. *Methods in Enzymology* **13** 3–5.
- Steel RGD & Torrie JH 1980 *Principles and Procedures of Statistics*, edn 2, pp 102–104, 137–153, 185–186. New York: McGraw-Hill.
- Tunbridge WMG & Caldwell G 1991 The epidemiology of thyroid diseases. In *The Thyroid: a Fundamental and Clinical Text*, edn 6, pp 578–587. Eds LE Braverman & RD Utiger. Philadelphia, PA: JB Lippincott.
- Uematsu M, Ohara Y, Navas JP, Nishida K, Murphy TJ, Alexander RW, Nerem RM & Harrison DG 1995 Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. *American Journal of Physiology – Cell Physiology* **269** C1371–C1378.
- Vargas F, Fernandez-Rivas A, Estan JG & del Rio CG 1995 Endothelium-dependent and endothelium-independent vasodilation in hyperthyroid and hypothyroid rats. *Pharmacology* **51** 308–314.
- Yen PM 2001 Physiological and molecular basis of thyroid hormone action. *Physiological Reviews* **81** 1097–1142.

Received 9 December 2004

Accepted 6 January 2005